



20 December, 2021

**PRESS RELEASE FOR IMMEDIATE USE**

**Dechra announces partnership with Bioiberica to boost companion animal offering in the United States**

Dechra is pleased to announce a joint collaboration with [Bioiberica](#), a global Life Science company committed to improving the health and well-being of people, animals and plants, for the license and distribution of its Atopivet® range of dermatology products for cats and dogs in the United States. The partnership complements Dechra's existing dermatology range and includes the products Atopivet® Collar, Atopivet® Spot-On, and Atopivet® Mousse.

Mike Eldred, President of Dechra North America, states: "The Atopivet® range of dermatology products strengthens Dechra's popular dermatology product line by offering several unique alternatives to multi-modal dermatology therapy."

Alfonso Velasco, Companion Animal Director at Bioiberica, adds: "Dermatological problems in canines are one of the most common reasons for veterinary clinic visits. We're delighted to be partnering with Dechra to bring our Atopivet® range to the United States. We're already looking ahead to how our collaboration can continue delivering new and innovative approaches to dermatology therapy, supporting the health and quality of life of pets across the region."

The Atopivet® range will be available in the United States in early 2022. For more information, visit: [www.dechra-us.com](http://www.dechra-us.com).

-----ENDS-----

**About Dechra:**

Dechra's companion animal portfolio focuses on endocrinology, dermatology, ophthalmology, anesthesia, fluid therapy, pain management, joint health support, and dental care. Our brands include Vetoryl® Capsules (trilostane), Zycortal® Suspension (desoxycorticosterone pivalate injectable suspension), Felimazole® Coated Tablets (methimazole), the Vetivex® line of parenteral fluids, and Phycox® joint health supplements. Osumnia® (florfenicol, terbinafine, betamethasone acetate) and the TrizUltra+Keto®,

MiconHex+Triz<sup>®</sup>, MalAcetic<sup>®</sup>, and oral anti-infective product lines, including Marboquin<sup>®</sup> (marbofloxacin) Tablets and Amoxicillin and Clavulanate Potassium for Oral Suspension, spotlight the dermatology offerings. And the recent addition of Mirataz<sup>®</sup> (mirtazapine transdermal ointment), Porus<sup>®</sup> One, and Redonyl<sup>®</sup> Ultra Feline to the portfolio supports the underserved feline market.

### **About Bioiberica:**

Bioiberica is a global Life Science company committed to improving the health and well-being of people, animals and plants with more than 45 years of experience. Bioiberica is a leader in the production of the Active Pharmaceutical Ingredient (API) Heparin and an expert in the identification, extraction and development of biologically-derived molecules, which are transformed into high quality products for the pharmaceutical, nutraceutical, veterinary, feed and agricultural sectors.

### **Contact:**

**Mike Eldred**  
President, North American Operations  
Dechra Veterinary Products  
[Mike.Eldred@Dechra.com](mailto:Mike.Eldred@Dechra.com)

**Doug Hubert**  
Vice President, Sales and Marketing  
Dechra Veterinary Products  
[Doug.Hubert@Dechra.com](mailto:Doug.Hubert@Dechra.com)

**Adriana Olivares**  
Communications Director  
Bioiberica  
[communications@bioiberica.com](mailto:communications@bioiberica.com)

**Emma Simms**  
Account Director  
BDB (Barret Dixon Bell)  
[bioiberica@bdb.co.uk](mailto:bioiberica@bdb.co.uk)